Metabolic Subtyping for Novel Personalized Therapies Against Pancreatic Cancer
Through metabolic subtyping, metabolic vulnerabilities can be exploited for developing efficacious treatments.
A glycolytic subtype indicates poor survival in pancreatic cancer patients, whereas a cholesterogenic subtype correlates with better outcomes potentially due to more energy expenditure. Read more . . .
